|
1
|
Romano S, Xiao Y, Nakaya M, D'Angelillo A,
Chang M, Jin J, Hausch F, Masullo M, Feng X, Romano MF, et al:
FKBP51 employs both scaffold and isomerase functions to promote
NF-κB activation in melanoma. Nucleic Acids Res. 43:6983–6993.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peterson M, Albertini MR and Remington P:
Incidence, Survival, and Mortality of Malignant Cutaneous Melanoma
in Wisconsin, 1995–2011. WMJ. 114:196–201. 2015.
|
|
3
|
Zehavi L, Schayek H, Jacob-Hirsch J, Sidi
Y, Leibowitz-Amit R and Avni D: MiR-377 targets E2F3 and alters the
NF-κB signaling pathway through MAP3K7 in malignant melanoma. Mol
Cancer. 14:682015. View Article : Google Scholar
|
|
4
|
Li J, Zhang Z and Li G: Patient outcome
prediction using multiple biomarkers in human melanoma: A
clinicopathological study of 118 cases. Exp Ther Med. 2:131–135.
2011.PubMed/NCBI
|
|
5
|
Gajos-Michniewicz A and Czyz M: Modulation
of WNT/β-catenin pathway in melanoma by biologically active
components derived from plants. Fitoterapia. 109:283–292. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Webter MR, Kuqel CH III and Weeraratna AT:
The Wnts of change: How Wnts regulate phenotype switching in
melanoma. Biochim Biophys Acta. 1856:244–251. 2015.
|
|
7
|
Daphu I, Horn S, Stieber D, Varughese JK,
Spriet E, Dale HA, Skaftnesmo KO, Bjerkvig R and Thorsen F: In
vitro treatment of melanoma brain metastasis by simultaneously
targeting the MAPK and PI3K signaling pathways. Int J Mol Sci.
15:8773–8794. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yajima I, Kumasaka MY, Thang ND, Goto Y,
Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y, et
al: RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant
melanoma progression and therapy. Dermatol Res Pract.
2012:3541912012.
|
|
9
|
Hu S, Luo Q, Cun B, Hu D, Ge S, Fan X and
Chen F: The pharmacological NF-κB inhibitor BAY11-7082 induces cell
apoptosis and inhibits the migration of human uveal melanoma cells.
Int J Mol Sc. 13:15653–15667. 2012. View Article : Google Scholar
|
|
10
|
Wu ZY, Lien JC, Huang YP, Liao CL, Lin JJ,
Fan MJ, Ko YC, Hsiao YP, Lu HF and Chung JG: Casticin inhibits
A375.S2 human melanoma cell migration/invasion through
downregulating NF-κB and matrix metalloproteinase-2 and -1.
Molecules. 21:3842016. View Article : Google Scholar
|
|
11
|
Li Y, Zu L, Wang Y, Wang M, Chen P and
Zhou Q: miR-132 inhibits lung cancer cell migration and invasion by
targeting SOX4. J Thorac Dis. 7:1563–1569. 2015.PubMed/NCBI
|
|
12
|
Song GD, Sun Y, Shen H and Li W: SOX4
overexpression is a novel biomarker of malignant status and poor
prognosis in breast cancer patients. Tumour Biol. 36:4167–4173.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao
X, Feng J, Zhang Y, Gao H, Liu DX, et al: SOX4 induces
epithelial-mesenchymal transition and contributes to breast cancer
progression. Cancer Res. 72:4597–4608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Zhang J, Yang X, Chang YW, Qi M,
Zhou Z, Zhang J and Han B: SOX4 is associated with poor prognosis
in prostate cancer and promotes epithelial-mesenchymal transition
in vitro. Prostate Cancer Prostatic Dis. 16:301–307. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vervoort SJ, van Boxtel R and Coffer PJ:
The role of SRY-related HMG box transcription factor 4 (SOX4) in
tumorigenesis and metastasis: Friend or foe? Oncogene.
32:3397–3409. 2013. View Article : Google Scholar
|
|
16
|
Aaboe M, Birkenkamp-Demtroder K, Wiuf C,
Sørensen FB, Thykjaer T, Sauter G, Jensen KM, Dyrskjøt L and
Ørntoft T: SOX4 expression in bladder carcinoma: Clinical aspects
and in vitro functional characterization. Cancer Res. 66:3434–3442.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jafarnejad SM, Wani AA, Martinka M and Li
G: Prognostic significance of Sox4 expression in human cutaneous
melanoma and its role in cell migration and invasion. Am J Pathol.
177:2741–2752. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang C, Zhao H, Lu J, Yin J, Zang L, Song
N, Dong R, Wu T and Du X: Clinicopathological significance of SOX4
expression in primary gallbladder carcinoma. Diagn Pathol.
7:412012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Harris ML, Baxter LL, Loftus SK and Pavan
WJ: Sox proteins in melanocyte development and melanoma. Pigment
Cell Melanoma Res. 23:496–513. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
Large-scale meta-analysis of cancer microarray data identifies
common transcriptional profiles of neoplastic transformation and
progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lefebvre V and Bhattaram P: SOXC genes and
the control of skeletogenesis. Curr Osteoporos Rep. 14:32–38. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang J, Jiang H, Shao J, Mao R, Liu J, Ma
Y, Fang X, Zhao N, Zheng S and Lin B: SOX4 inhibits GBM cell growth
and induces G0/G1 cell cycle arrest through Akt-p53 axis. BMC
Neurol. 14:2072014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kumar A, Takada Y, Boriek AM and Aggarwal
BB: Nuclear factor-kappaB: Its role in health and disease. J Mol
Med (Berl). 82:434–448. 2004. View Article : Google Scholar
|
|
24
|
Emdad L, Sarkar D, Su ZZ, Randolph A,
Boukerche H, Valerie K and Fisher PB: Activation of the nuclear
factor kappaB pathway by astrocyte elevated gene-1: Implications
for tumor progression and metastasis. Cancer Res. 66:1509–1516.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Aggarwal BB and Sung B: NF-κB in cancer: A
matter of life and death. Cancer Discov. 1:469–471. 2011.
View Article : Google Scholar
|
|
26
|
Amiri KI and Richmond A: Role of nuclear
factor-kappa B in melanoma. Cancer Metastasis Rev. 24:301–313.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ryu B, Kim DS, Deluca AM and Alani RM:
Comprehensive expression profiling of tumor cell lines identifies
molecular signatures of melanoma progression. PLoS One. 2:e5942007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim A, Kim MJ, Yang Y, Kim JW, Yeom YI and
Lim JS: Suppression of NF-kappaB activity by NDRG2 expression
attenuates the invasive potential of highly malignant tumor cells.
Carcinogenesis. 30:927–936. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hong IK, Kim YM, Jeoung DI, Kim KC and Lee
H: Tetraspanin CD9 induces MMP-2 expression by activating p38 MAPK,
JNK and c-Jun pathways in human melanoma cells. Exp Mol Med.
37:230–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seftor RE, Seftor EA, Koshikawa N, Meltzer
PS, Gardner LM, Bilban M, Stetler-Stevenson WG, Quaranta V and
Hendrix MJ: Cooperative interactions of laminin 5 gamma2 chain,
matrix metalloproteinase-2, and membrane
type-1-matrix/metalloproteinase are required for mimicry of
embryonic vasculogenesis by aggressive melanoma. Cancer Res.
61:6322–6327. 2001.PubMed/NCBI
|
